U.S., Dec. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07274059) titled 'Allogeneic UCB-derived CAR-T for SLE' on Nov. 22.
Brief Summary: The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) targeting CD19 and BCMA works to treat refractory SLE in adults. It will also learn about the safety and efficacy of the UCAR-T cell product.
Study Start Date: March 26
Study Type: INTERVENTIONAL
Condition:
SLE - Systemic Lupus Erythematosus
Intervention:
DRUG: allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA
intravenous injection of allogeneic umbilical cord blood-derived CAR-T targeting CD19 and BCMA
Recruit...